Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.
about
Modulating non-native aggregation and electrostatic protein-protein interactions with computationally designed single-point mutationsCDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery.Stability engineering of scFvs for the development of bispecific and multivalent antibodies.A dual-targeting PDGFRbeta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo.A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.O-glycosylation of glycine-serine linkers in recombinant Fc-fusion proteins: attachment of glycosaminoglycans and other intermediates with phosphorylation at the xylose sugar subunit.Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activityRapid optimization and prototyping for therapeutic antibody-like molecules.Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domainImmunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodiesA stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activityFab-based bispecific antibody formats with robust biophysical properties and biological activityRearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokineticsA Combination of Structural and Empirical Analyses Delineates the Key Contacts Mediating Stability and Affinity Increases in an Optimized Biotherapeutic Single-chain Fv (scFv).Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.Engineering the variable region of therapeutic IgG antibodies.Emerging antibody combinations in oncology.Dual targeting strategies with bispecific antibodies.Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.Multi-specific antibodies for cancer immunotherapy.Biological Insights into Therapeutic Protein Modifications throughout Trafficking and Their Biopharmaceutical Applications.Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains.Comparing domain interactions within antibody Fabs with kappa and lambda light chains.Neutralization of Clostridium difficile toxin A using antibody combinations.A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens.Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies.Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy.Thermodynamic stability and flexibility characteristics of antibody fragment complexes.The making of bispecific antibodies6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of the Antibody Society. December 5-9, 2010, San Diego, CA USA.Rational engineering of antibody therapeutics targeting multiple oncogene pathways.Highly covarying residues have a functional role in antibody constant domains.Computational design of a specific heavy chain/κ light chain interface for expressing fully IgG bispecific antibodies.Purification of common light chain IgG-like bispecific antibodies using highly linear pH gradients.Quantitative analysis of cell surface antigen-antibody interaction using Gaussia princeps luciferase antibody fusion proteins.Structural considerations for functional anti-EGFR × anti-CD3 bispecific diabodies in light of domain order and binding affinity.Development of a novel recombinant biotherapeutic with applications in targeted therapy of human arthritisDesign, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells
P2860
Q30276839-86C3C587-5F9A-41C9-8C64-24E60F8ED8D3Q31135534-6A1ECC9A-D9B0-4E26-8B37-70DEE16D3F29Q33574335-EB814070-FF5E-4522-B3DB-4A4B990F275DQ33688219-C8708F1E-F248-41EC-85CF-EC4701A0EA24Q33846405-60E7B588-FE35-4BE7-8EF5-E1046FA76CB1Q34223974-153B8394-2875-4BF5-8D55-11F439E44538Q34575855-0C1AF253-8584-49E2-820D-555CD8845115Q34580658-573BC8C8-7523-43F0-B73A-2E435CD3D695Q34724092-42539E5F-A150-48A3-92E3-1757EBB86BA0Q35090965-482370C4-112E-40AF-924A-8818C3B21D03Q35146077-80026197-D12C-4A88-9A6A-5C4AB29D03B7Q36213193-7670CCC4-BDCF-4E49-9329-2823A3A2188FQ36216009-94B171C9-0D36-4437-A2E4-87DCDE47B143Q36466175-A9E9D255-AEC0-41A0-A291-F196FB0316BEQ37141599-482080D9-0AF8-4F97-BAB7-7E3F9B0BC3D3Q37853324-8301B97B-9B75-48C7-9411-B0617AE4D868Q37893414-0FDDDF15-9DB1-499E-BD89-24268894F386Q37997559-C11B2DD1-0577-4EB9-B3CB-4332473E4135Q38074885-33DDC3E2-DDEA-4065-BC0A-4692644BB67FQ38196723-5D5A624C-878D-4DA7-AB73-B82291374547Q39149359-4B1EBF86-37E4-444C-AC8D-2153EB91F066Q39435224-EB3AB575-229A-4D9A-AD13-0CCD57014DC5Q39563946-9D8C7033-AF9B-4591-999E-EB9B23FA4AA7Q39664838-1D605123-0C12-4396-9F60-35A450A5A399Q39917871-41278B3F-0AB5-413F-8D46-4A66E06E0E57Q41838529-108788B8-12D8-4E71-9813-B43E5CFF42AEQ42153659-9C8E98EF-7286-4D7A-9E8B-39DA3373D354Q42204547-56B14F7E-3FF6-4491-8115-819FE3CA11D4Q42323236-CEFDCA3A-22EE-4AC1-B514-6B80097AABAEQ42732008-34BF3A69-F5F5-48AB-A5A1-B47E861C03E6Q42732010-22A17474-3320-4092-ADA2-104DA5C5F14AQ42854245-DACF0D80-0000-4EB5-B09C-574139D98F5CQ44243757-824F24A5-F236-434A-B207-6C74FAB940CDQ45037117-D27715FB-16C3-477F-BBDE-056C2B287AE1Q50323216-6A89377B-A06D-4CDC-9E15-A7EA0CCBC82DQ51186812-3E71D6C7-5EAE-4618-8A8F-1B582BA747C4Q52641571-311B72F6-6BFD-4D29-8884-F33A9AB934DEQ56892563-A613F2DD-16FE-4D83-B094-59164A5F9B36Q59134014-3BD4FEF7-3DDA-4E2C-A7C5-AD05F1212926
P2860
Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Anti-tumor activity of stabili ...... argeting TRAIL-R2 and LTbetaR.
@en
Anti-tumor activity of stabili ...... argeting TRAIL-R2 and LTbetaR.
@nl
type
label
Anti-tumor activity of stabili ...... argeting TRAIL-R2 and LTbetaR.
@en
Anti-tumor activity of stabili ...... argeting TRAIL-R2 and LTbetaR.
@nl
prefLabel
Anti-tumor activity of stabili ...... argeting TRAIL-R2 and LTbetaR.
@en
Anti-tumor activity of stabili ...... argeting TRAIL-R2 and LTbetaR.
@nl
P2093
P2860
P356
P1476
Anti-tumor activity of stabili ...... argeting TRAIL-R2 and LTbetaR.
@en
P2093
Adam Doern
Aldo Amatucci
Alexey Lugovskoy
Brian Miller
Ellen Garber
Flora Huang
Graham K Farrington
Ingrid Joseph
Jeff Browning
Jennifer S Michaelson
P2860
P304
P356
10.4161/MABS.1.2.7631
P577
2009-03-11T00:00:00Z